Education
About Us
Working with TipRanks
Follow Us
Embecta Corporation (EMBC)
NASDAQ:EMBC
EMBC Stock Chart & Stats
$10.86
$0.16(0.83%)
At close: 4:00 PM EST
$10.86
$0.16(0.83%)
Day’s Range― - ―
52-Week Range$9.20 - $18.06
Previous CloseN/A
Volume119.84K
Average Volume (3M)559.70K
Market Cap
$619.95M
Enterprise Value$1.86B
Total Cash (Recent Filing)$204.40M
Total Debt (Recent Filing)$1.42B
Price to Earnings (P/E)4.4
Beta0.94
Next Earnings
May 08, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend Yield5.03%
Share Statistics
EPS (TTM)0.71
Shares Outstanding59,211,990
10 Day Avg. Volume840,216
30 Day Avg. Volume559,700
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)-1.26
Price to Sales (P/S)0.76
P/FCF Ratio4.51
Enterprise Value/Market Cap3.00
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda5.36
Forecast
1Y Price Target
$25.00Price Target Upside130.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.89
Revenue Forecast (FY)$1.08B
Bulls Say, Bears Say
Bulls Say
Brand Transition And Pipeline InitiativesThe company is nearly done with its brand transition in the U.S. and Canada, and is progressing on pipeline initiatives such as pen needles for generic GLP-1 administration.
Debt Reduction And Cost SavingsEMBC expects to reduce its debt by $150M this fiscal year while simultaneously driving $7M-$8M in pre-tax cost savings in the second half of the fiscal year.
Growth In Emerging MarketsEmerging markets continue to be a source of growth as EMBC plans to introduce products to meet local market needs in new regions.
Bears Say
Chinese Market ConcernsEMBC expressed near-term concern about the Chinese market, where distributors have reported customers buying more local Chinese brands as a result of tariffs and recent geopolitical tensions.
Revenue Decrease ExpectationThe full-year guide implies a ~$30M sequential decrease in revenue for F4Q at the midpoint, reflecting the reversal of the benefits from timing of distributor orders and stocking in F3Q, in addition to rebate reserve adjustments.
Embecta Corporation News
EMBC FAQ
What was Embecta Corporation’s price range in the past 12 months?
Embecta Corporation lowest stock price was $9.20 and its highest was $18.06 in the past 12 months.
What is Embecta Corporation’s market cap?
Embecta Corporation’s market cap is $619.95M.
When is Embecta Corporation’s upcoming earnings report date?
Embecta Corporation’s upcoming earnings report date is May 08, 2026 which is in 89 days.
How were Embecta Corporation’s earnings last quarter?
Embecta Corporation released its earnings results on Feb 05, 2026. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.671 by $0.039.
Is Embecta Corporation overvalued?
According to Wall Street analysts Embecta Corporation’s price is currently Undervalued.
Does Embecta Corporation pay dividends?
Embecta Corporation pays a Quarterly dividend of $0.15 which represents an annual dividend yield of 5.03%. See more information on Embecta Corporation dividends here
What is Embecta Corporation’s EPS estimate?
Embecta Corporation’s EPS estimate is 0.42.
How many shares outstanding does Embecta Corporation have?
Embecta Corporation has 59,211,990 shares outstanding.
What happened to Embecta Corporation’s price movement after its last earnings report?
Embecta Corporation reported an EPS of $0.71 in its last earnings report, beating expectations of $0.671. Following the earnings report the stock price went down -7.753%.
Which hedge fund is a major shareholder of Embecta Corporation?
Currently, no hedge funds are holding shares in EMBC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Embecta Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (130.20% Upside)
$25.00 (130.20% Upside)
Blogger Sentiment
Neutral
EMBC Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 359.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.46%
Trailing 12-Months
Company Description
Embecta Corporation
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
EMBC Company Deck
EMBC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed mixed near-term operational challenges—notably U.S. pricing and volume headwinds, pen needle declines, China weakness and a meaningful drop in contract manufacturing—balanced against several strategic and financial positives: strong international growth (EMEA and Latin America), category growth in syringes and safety products, meaningful progress on brand transition and Medicare Part D access, tangible GLP-1 commercial traction with >30 partners and executed purchase orders, continued deleveraging (net leverage ~2.8x) and improved GAAP profitability metrics. Management reaffirmed guidance but signaled being nearer the low end due to U.S. pressures. Overall, the call emphasized execution on multi-year strategic initiatives and financial stability, while acknowledging near-term headwinds that temper upside.View all EMBC earnings summariesEMBC Stock 12 Month Forecast
Average Price Target
$25.00
▲(130.20% Upside)
Technical Analysis
Dynavax
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
Collegium Pharmaceutical
―
Organogenesis Holdings
―
Ownership Overview
3.16% Insiders
31.12% Mutual Funds
0.88% Other Institutional Investors
39.56% Public Companies and
Individual Investors